IP Library › Patent Application 15580979
Patent Application
App. No. 15/580,979

THERAPEUTIC AGENT FOR NEUROTROPHIC KERATOPATHY

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
15/580,979
Abstract

Provided are a novel pharmaceutical use of PPARδ agonist such as a therapeutic agent for neurotrophic keratopathy, an improving agent for decrease of corneal sensitivity and the like, each containing [3-[2-[4-isopropyl-2-(4-trifluoromethyl)phenyl-5-thiazolyl]ethyl]-5-methyl-1,2-benzisoxazol-6-yl]oxyacetic acid or a pharmacologically acceptable salt thereof.

Claims (9)

1 . A therapeutic agent for neurotrophic keratopathy comprising [3-[2-[4-isopropyl-2-(4-trifluoromethyl)phenyl-5-thiazolyl]ethyl]-5-methyl-1,2-benzisoxazol-6-yl]oxyacetic acid or a pharmacologically acceptable salt thereof.

2 . The therapeutic agent according to claim 1 , wherein the neurotrophic keratopathy is neurotrophic keratopathy caused by diabetes.

3 . The therapeutic agent according to claim 2 , wherein the neurotrophic keratopathy caused by diabetes is diabetic keratopathy.

4 . An agent for improving decrease of corneal sensitivity, comprising [3-[2-[4-isopropyl-2-(4-trifluoromethyl)phenyl-5-thiazolyl]ethyl]-5-methyl-1,2-benzisoxazol-6-yl]oxyacetic acid or a pharmacologically acceptable salt thereof.

5 - 8 . (canceled)

9 . A method of treating neurotrophic keratopathy, comprising administering an effective amount of [3-[2-[4-isopropyl-2-(4-trifluoromethyl)phenyl-5-thiazolyl]ethyl]-5-methyl-1,2-benzisoxazol-6-yl]oxyacetic acid or a pharmacologically acceptable salt thereof to a subject in need of a treatment of neurotrophic keratopathy.

10 . The method according to claim 9 , wherein the neurotrophic keratopathy is neurotrophic keratopathy caused by diabetes.

11 . The method according to claim 10 , wherein the neurotrophic keratopathy caused by diabetes is diabetic keratopathy.

12 . A method of improving decrease of corneal sensitivity, comprising administering an effective amount of [3-[2-[4-isopropyl-2-(4-trifluoromethyl)phenyl-5-thiazolyl]ethyl]-5-methyl-1,2-benzisoxazol-6-yl]oxyacetic acid or a pharmacologically acceptable salt thereof to a subject in need of an improvement of decrease of corneal sensitivity.

Assignments (2)
CHANGE OF ADDRESS Recorded Aug 24, 2018
From: SENJU PHARMACEUTICAL CO., LTD.
To: SENJU PHARMACEUTICAL CO., LTD.
Reel/Frame 046835/0350 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 11, 2018
From: KOBAYASHI, SHINYA; NAKAMURA, YOSHIKUNI; TARUI, TAKESHI; WADA, TOMOYUKI
To: SENJU PHARMACEUTICAL CO., LTD.
Reel/Frame 044594/0165 →